Parent Project Muscular Dystrophy and Italfarmaco hosted a webinar on April 26, 2017 to discuss Italfarmaco’s investigational drug Givinostat (a histone deacetylase (HDAC) inhibitor) and how it works in Duchenne. Our speakers presented a brief history of the development program, including pre-clinical results and preliminary results of the current Phase 2 clinical trial, study 43, which is ongoing in Italy, and answered questions from our community.
by: Parent Project Muscular Dystrophy
